CN1235914C - 含有至少一个具有生物素或生物素衍生物共价键的具有抗血栓形成活性的多糖 - Google Patents

含有至少一个具有生物素或生物素衍生物共价键的具有抗血栓形成活性的多糖 Download PDF

Info

Publication number
CN1235914C
CN1235914C CNB018161588A CN01816158A CN1235914C CN 1235914 C CN1235914 C CN 1235914C CN B018161588 A CNB018161588 A CN B018161588A CN 01816158 A CN01816158 A CN 01816158A CN 1235914 C CN1235914 C CN 1235914C
Authority
CN
China
Prior art keywords
methyl
glucopyranosyl
tri
group
sulfonato
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018161588A
Other languages
English (en)
Chinese (zh)
Other versions
CN1466594A (zh
Inventor
P·迪绍索伊
J·－M·赫尔伯特
M·佩蒂托
P·萨维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Akzo Nobel NV
Original Assignee
Sanofi Synthelabo SA
Sanofi Aventis France
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Sanofi Aventis France, Akzo Nobel NV filed Critical Sanofi Synthelabo SA
Publication of CN1466594A publication Critical patent/CN1466594A/zh
Application granted granted Critical
Publication of CN1235914C publication Critical patent/CN1235914C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CNB018161588A 2000-09-22 2001-09-20 含有至少一个具有生物素或生物素衍生物共价键的具有抗血栓形成活性的多糖 Expired - Fee Related CN1235914C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012094A FR2814463B1 (fr) 2000-09-22 2000-09-22 Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
FR00/12094 2000-09-22

Publications (2)

Publication Number Publication Date
CN1466594A CN1466594A (zh) 2004-01-07
CN1235914C true CN1235914C (zh) 2006-01-11

Family

ID=8854579

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018161588A Expired - Fee Related CN1235914C (zh) 2000-09-22 2001-09-20 含有至少一个具有生物素或生物素衍生物共价键的具有抗血栓形成活性的多糖

Country Status (39)

Country Link
US (3) US6844329B2 (enExample)
EP (1) EP1322673B1 (enExample)
JP (2) JP5016778B2 (enExample)
KR (2) KR20080049139A (enExample)
CN (1) CN1235914C (enExample)
AR (1) AR030774A1 (enExample)
AT (1) ATE374215T1 (enExample)
AU (2) AU2001291960C1 (enExample)
BG (1) BG66191B1 (enExample)
BR (1) BR0114007A (enExample)
CA (1) CA2418815C (enExample)
CY (1) CY1108076T1 (enExample)
CZ (1) CZ300856B6 (enExample)
DE (1) DE60130669T2 (enExample)
DK (1) DK1322673T3 (enExample)
EA (1) EA005133B1 (enExample)
EC (1) ECSP034514A (enExample)
EE (1) EE05202B1 (enExample)
ES (1) ES2292625T3 (enExample)
FR (1) FR2814463B1 (enExample)
GE (1) GEP20053616B (enExample)
HR (1) HRP20030219B1 (enExample)
HU (2) HUP0303551A3 (enExample)
IL (2) IL154848A0 (enExample)
IS (1) IS2550B (enExample)
ME (2) MEP23608A (enExample)
MX (1) MXPA03002483A (enExample)
NO (2) NO332905B1 (enExample)
NZ (1) NZ524472A (enExample)
PE (1) PE20020471A1 (enExample)
PL (1) PL206727B1 (enExample)
PT (1) PT1322673E (enExample)
RS (1) RS50730B (enExample)
SI (1) SI1322673T1 (enExample)
SK (2) SK287218B6 (enExample)
TW (1) TWI308153B (enExample)
UA (1) UA79736C2 (enExample)
WO (1) WO2002024754A1 (enExample)
ZA (1) ZA200301692B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
FR2874924B1 (fr) * 2004-09-09 2006-12-01 Sanofi Aventis Sa Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
CN101312747B (zh) * 2005-10-10 2013-03-20 Msd欧斯股份有限公司 包括生物素标记的抗血栓形成双重抑制剂
BRPI0617215A2 (pt) * 2005-10-10 2011-07-19 Organon Nv composto anti-trombótico, composição farmacêutica, e, uso do composto
CN1317035C (zh) * 2005-10-24 2007-05-23 天津大学 基于酰肼基的微粒表面多重生物功能因子组装方法
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
FR2912409B1 (fr) * 2007-02-14 2012-08-24 Sanofi Aventis Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine leur procede de preparation,leur utilisation
TW201006479A (en) * 2008-07-18 2010-02-16 Sanofi Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2233143A1 (en) 2009-03-24 2010-09-29 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
FR2935386B1 (fr) * 2008-08-26 2010-09-10 Sanofi Aventis Nouveaux polysaccharides a activite antithrombotique comprenant une liaion covalente avec une chaine amine
US20110150976A1 (en) * 2008-09-10 2011-06-23 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
MX2011006463A (es) 2008-12-19 2011-07-20 Supernus Pharmaceuticals Inc Metodo de tratamiento de agresion.
FR2952935B1 (fr) * 2009-11-20 2011-12-02 Sanofi Aventis Procede de preparation du n-biotinyl-6-aminocaproate de n succinimidyle
US9259389B2 (en) 2009-12-18 2016-02-16 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CZ302669B6 (cs) * 2010-03-29 2011-08-24 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace aminosloucenin pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
CZ302510B6 (cs) * 2010-03-29 2011-06-22 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace sloucenin s karboxylovou skupinou pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
US8748472B2 (en) 2010-03-31 2014-06-10 Supernus Pharmaceuticals, Inc. Stabilized formulations of CNS compounds
WO2012042123A1 (fr) 2010-09-10 2012-04-05 Sanofi Polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
FR2964660B1 (fr) * 2010-09-10 2012-09-28 Sanofi Aventis Nouveaux polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
EP2484366A1 (en) 2011-02-07 2012-08-08 Sanofi Idrabiotaparinux for the treatment of pulmonary embolism and for the secondary prevention of venous thromboembolic events
JP6051211B2 (ja) * 2011-06-17 2016-12-27 カルボミメティクス 半減期が短く活性が高い合成五糖類
US20140135326A1 (en) * 2012-11-13 2014-05-15 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
WO2015195404A1 (en) 2014-06-20 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detection of an analyte by movement of tethered microparticles
WO2016205239A1 (en) 2015-06-15 2016-12-22 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Non-hormonal mammalian sperm decoy contraception based on the n-terminus of the zp2 protein
JP7492826B2 (ja) 2016-10-21 2024-05-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 分子ナノタグ
CN108976318B (zh) * 2017-06-01 2021-03-30 首都医科大学 单-6-(生物素酰胺基)-6-脱氧-β-环糊精及其制备方法和应用
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
WO2021007429A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
CN114556685B (zh) * 2019-10-17 2024-04-02 株式会社自动网络技术研究所 布线模块
WO2022056078A1 (en) 2020-09-11 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rnase h-assisted detection assay for rna (radar)
WO2024191684A1 (en) 2023-03-10 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection of hepatitis c virus ribonucleic acid from whole blood using reverse transcription loop-mediated isothermal amplification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960884A (en) * 1974-04-24 1976-06-01 Sergei Ivanovich Zavyalov Method of preparing racemic biotin
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
FR2751334B1 (fr) * 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
GB2335490B (en) * 1998-03-20 2003-05-14 Ortho Clinical Diagnostics An assay surface that permits an analyte releasiing step
AU8366398A (en) * 1998-07-07 2000-01-24 Department Of Radiation Oncology University Of Washington Trifunctional reagent for conjugation to a biomolecule
EP1022289B1 (en) 1998-07-31 2004-07-07 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine

Also Published As

Publication number Publication date
ECSP034514A (es) 2003-04-25
ES2292625T3 (es) 2008-03-16
MXPA03002483A (es) 2004-05-24
RS50730B (sr) 2010-08-31
PE20020471A1 (es) 2002-06-01
AU2001291960C1 (en) 2009-10-08
EE05202B1 (et) 2009-08-17
KR100891388B1 (ko) 2009-04-02
CN1466594A (zh) 2004-01-07
BR0114007A (pt) 2003-08-12
US20110144042A1 (en) 2011-06-16
DE60130669T2 (de) 2008-07-17
FR2814463B1 (fr) 2002-11-15
CY1108076T1 (el) 2014-02-12
ME00080B (me) 2010-10-10
YU19703A (sh) 2006-05-25
EP1322673A1 (fr) 2003-07-02
GEP20053616B (en) 2005-09-26
ZA200301692B (en) 2004-03-01
ATE374215T1 (de) 2007-10-15
NO332905B1 (no) 2013-01-28
HRP20030219B1 (hr) 2011-10-31
SK287054B6 (sk) 2009-10-07
NO20110401L (no) 2003-05-22
EA005133B1 (ru) 2004-12-30
US20060160768A1 (en) 2006-07-20
KR20080049139A (ko) 2008-06-03
IS2550B (is) 2009-10-15
UA79736C2 (uk) 2007-07-25
AR030774A1 (es) 2003-09-03
CA2418815C (en) 2011-05-10
EA200300237A1 (ru) 2003-08-28
EE200300114A (et) 2005-02-15
BG107650A (bg) 2003-11-28
DE60130669D1 (de) 2007-11-08
HUP0303551A3 (en) 2004-03-29
AU2001291960B2 (en) 2007-03-01
US20040024197A1 (en) 2004-02-05
AU9196001A (en) 2002-04-02
CZ300856B6 (cs) 2009-08-26
IL154848A (en) 2010-11-30
JP5016778B2 (ja) 2012-09-05
SK287218B6 (sk) 2010-03-08
PT1322673E (pt) 2007-12-03
JP2012131809A (ja) 2012-07-12
SK3562003A3 (en) 2003-11-04
TWI308153B (en) 2009-04-01
US8318696B2 (en) 2012-11-27
CZ2003814A3 (cs) 2003-06-18
IS6733A (is) 2003-02-28
HUP0303551A2 (hu) 2004-03-01
HU1400034D0 (hu) 2004-03-01
NO20031295L (no) 2003-05-22
BG66191B1 (bg) 2011-12-30
FR2814463A1 (fr) 2002-03-29
PL363368A1 (en) 2004-11-15
WO2002024754A1 (fr) 2002-03-28
KR20030055269A (ko) 2003-07-02
WO2002024754A8 (fr) 2003-07-03
IL154848A0 (en) 2003-10-31
CA2418815A1 (en) 2002-03-28
US6844329B2 (en) 2005-01-18
HK1053316A1 (zh) 2003-10-17
HRP20030219A2 (en) 2003-06-30
NO20031295D0 (no) 2003-03-20
EP1322673B1 (fr) 2007-09-26
US7943595B2 (en) 2011-05-17
MEP23608A (bs) 2010-06-10
JP2004509902A (ja) 2004-04-02
SI1322673T1 (sl) 2008-02-29
DK1322673T3 (da) 2008-01-14
PL206727B1 (pl) 2010-09-30
NZ524472A (en) 2004-10-29

Similar Documents

Publication Publication Date Title
CN1235914C (zh) 含有至少一个具有生物素或生物素衍生物共价键的具有抗血栓形成活性的多糖
CN1200003C (zh) 合成多糖、其制备方法以及含有它们的药物组合物
CN1165550C (zh) 合成多糖和含有它们的药物组合物以及其用途
CN1045302C (zh) 新型(神经)鞘糖脂、含有它们的药物组合物及其用途
CN1227034C (zh) 药物复合物的制造方法
CN1051228C (zh) 含透明质酸配合物的药物组合物的制备方法
JP3476455B2 (ja) ＮｅｕＡｃα２、６Ｇａｌβ１、４ＧｌｃＮＡｃ及びシアリルＬｅｘの合成法
CN1558911A (zh) 合成肝素五糖
CN1058598A (zh) 新型生物活性缀合物
CN1076124A (zh) 一种用于制备含有酸不稳定化合物的肠溶衣口服药的方法
CN1283224A (zh) 透明质酸合酶基因及其应用
CN1099038A (zh) 3-脱氧低聚糖，其制备方法和含有它们的药物组合物
CN1906203A (zh) 葡糖胺基聚糖(gag)模拟物
CN1917886A (zh) 核心2GlcNAc－T抑制剂
CN1172948C (zh) 新的五糖及其制备方法和含有它们的药物组合物
CN1073359A (zh) 亲脂寡糖抗生素组合物
CN1176644A (zh) 路易斯x衍生物及其制备方法
CN1665829A (zh) 非甾类抗炎物质、组合物及其使用方法
CN1295251C (zh) 由k5多糖衍生具有高抗血栓形成活性的糖胺聚糖及其制备方法
CN1042546A (zh) 抗体-药物结合物
CN1062537A (zh) 新的肝素衍生物
CN1126752C (zh) 神经氨酸化合物
CN1191261C (zh) 硫酸化岩藻半乳聚糖
CN101039963A (zh) 生物素化十六糖，它们的制备方法及其用途
CN1694728A (zh) 用于传递治疗剂的以环糊精为基础的聚合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060111

Termination date: 20180920